Evidence map›Paper›PMID 40274806›Full record

ArticleNPJ Parkinson's disease2025

Improvement of apathy in early Parkinson's disease.

A Castrioto, E Schmitt, M Anheim, S Meoni, H Klinger, D Sourd, P Pelissier, E Lhommée, A Bichon, C Tranchant and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

A CastriotoUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France. acastrioto@chu-grenoble.fr.
E SchmittUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France.
M AnheimDépartement de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
S MeoniUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France.
H KlingerHospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Réanimation Neurologique, Hôpital Louis Pradel, Réanimation Chirurgicale, Bron, France.
D SourdUniv. Grenoble Alpes, Data Engineering Unit, Public Health Department, Grenoble Alpes University Hospital, Grenoble, France.
P PelissierUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France.
E LhomméeUniv. Grenoble Alpes, UMR CNRS 5105 Neuropsychology and NeuroCognition, CHU Grenoble Alpes, Dept of NeuroRehabilitation South Hospital, Grenoble, France.
A BichonCHU Grenoble-Alpes, Service universitaire de Gériatrie et Gérontologie Clinique, Grenoble, France.
C TranchantDépartement de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
E MoroUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France.
V FraixUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France.
S ThoboisHospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Parkinson expert center, Bron, France France; NS-PARK, Bron, France.
P KrackDepartment of Neurology, Inselspital, University Hospital Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apathy is a disabling symptom in Parkinson's disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug naive PD patients for 4 years, after dopaminergic treatment introduction. The main objective of the study was the change of apathy from baseline to follow-up and secondary outcomes were the change of other neuropsychiatric symptoms. At 4 years there was an improvement of apathy (p = 0.002), mainly driven by improvement of baseline apathy (p = 0.001). This was associated with an improvement of anxiety (p = 0.001), an increase in hyperdopaminergic behavior including nocturnal hyperactivity with consecutive diurnal sleepiness (p = 0.001 and p < 0.001), independently of the presence of apathy at baseline. These findings confirm, in a large real-life cohort, that dopaminergic treatment improves motivational apathy in early PD.

Identifiers

PMID40274806
PMCPMC12022347

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.